Effects of treatment change in patients with neovascular age-related macular degeneration; results from the Czech National Registry

Biomedical Papers

Volumn 156, Issue 4, 2012, Pages 359-364

  Studnicka, Jan ^a   Rencova, Eva ^a   Rozsival, Pavel ^a   Dusova, Jaroslava ^a   Dubska, Zora ^b   Chrapek, Oldrich ^c   Kolar, Petr ^d   Kandrnal, Vit ^e   Pitrova, Sarka ^f   Rehak, Jiri ^c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e MASARYK UNIVERSITY   (Czech Republic)

^f Private Urological Clinic   (Czech Republic)

Author keywords

Age related macular degeneration; Choroidal neovascular membrane; Pegaptanib; Photodynamic therapy with verteporfin; Ranibizumab; Visual acuity

Indexed keywords

APTAMER; MONOCLONAL ANTIBODY; PEGAPTANIB; RANIBIZUMAB;

AGED; ARTICLE; CZECH REPUBLIC; FEMALE; HUMAN; MALE; MULTICENTER STUDY; REGISTER; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY; TREATMENT FAILURE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CZECH REPUBLIC; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84872047341     PISSN: 12138118     EISSN: 18047521     Source Type: Journal    
DOI: 10.5507/bp.2012.100     Document Type: Article

References (10)

1. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. Int Ophthalmol Clin 2004;44:17-39.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
3. Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration. Ophthalmology 2008;115: 116-26.
4. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib sodium, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-32.
5. Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shin V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85:425-30.
6. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999;117:1329-45.
7. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
8. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566-83.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib sodium for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
10. Quiram PA, Hassan TS, Williams GA. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib sodium. Retina 2007; 27:851-6.